Citation Impact
Citing Papers
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America
2009 Standout
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
2004 StandoutScience
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Infective Endocarditis
2005 Standout
β-lactams against methicillin-resistant
2005
Primary DNA Damage But Not Mutagenicity Correlates with Ciprofloxacin Concentrations in German Hospital Wastewaters
1999
Efflux-Mediated Drug Resistance in Bacteria
2004
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Low-level antibacterial resistance: a gateway to clinical resistance
2001
Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY antimicrobial surveillance program
2003
The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America
2007 Standout
Antibiotics in the aquatic environment – A review – Part I
2009 Standout
Fluoroquinolone resistance among Gram-positive cocci
2002
New Consensus Guidelines from the Clinical and Laboratory Standards Institute for Antimicrobial Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria
2006 Standout
The Bacterial Cell Envelope
2010 Standout
Optical control of antibacterial activity
2013 StandoutNobel
Antibiotics in the aquatic environment – A review – Part II
2009 Standout
Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis*
2010
Structural basis for the β lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus
2002
What is a resistance gene? Ranking risk in resistomes
2014 Standout
A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study
2010
Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure
2001
Recent developments in pradimicin-benanomicin and triazole antibiotics
1997
Methods for in vitro evaluating antimicrobial activity: A review
2015 Standout
Antibiotic resistance and its cost: is it possible to reverse resistance?
2010 Standout
Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
2006 Standout
Emergence of Levofloxacin-Resistant Pneumococci in Immunocompromised Adults after Therapy for Community-Acquired Pneumonia
2003
Methicillin-Resistant Staphylococcus aureus: An Evolutionary, Epidemiologic, and Therapeutic Odyssey
2005
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
2005 Standout
Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development
1998
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Catechol‐Based Biomimetic Functional Materials
2012
The Future of Antifungal Therapy
1996
Fluoroquinolones: Action and Resistance
2003
Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997–2000)
2002
Vertebral Osteomyelitis
2010 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection
2000
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
Mechanism of Quinolone Action and Resistance
2014 Standout
Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections
2008
Solving staphylococcal resistance to β-lactams
2003
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
The Need for New Drugs against Tuberculosis
2001
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in U.S. Streams, 1999−2000: A National Reconnaissance
2002 Standout
Molecular Basis of Bacterial Outer Membrane Permeability Revisited
2003 Standout
The role of specific surface loop regions in determining the function of the imipenem-specific pore protein OprD of Pseudomonas aeruginosa
1996
Quinolone Resistance Due to Reduced Target Enzyme Expression
2003
Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance
1999 Standout
Mutation Frequencies and Antibiotic Resistance
2000
Current and Emerging Azole Antifungal Agents
1999 Standout
AmpC β-Lactamases
2009 Standout
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
2011 Standout
From conference abstract to full paper: differences between data presented in conferences and journals
2005
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
2005 Standout
In Vitro Activities of Newer Quinolones against Bacteroides Group Organisms
2002
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
1996
International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
2011 Standout
In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346)
1998
Full publication of results initially presented in abstracts
2007 Standout
Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group
1997
Synergie et antagonisme en antibiothérapie
2009
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Biochemical-Genetic Characterization and Distribution of OXA-22, a Chromosomal and Inducible Class D β-Lactamase fromRalstonia(Pseudomonas)pickettii
2000
Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination
2007
Granular Layer in the Periplasmic Space of Gram-Positive Bacteria and Fine Structures ofEnterococcus gallinarumandStreptococcus gordoniiSepta Revealed by Cryo-Electron Microscopy of Vitreous Sections
2006 StandoutNobel
Klebsiellaspp. as Nosocomial Pathogens: Epidemiology, Taxonomy, Typing Methods, and Pathogenicity Factors
1998 Standout
Polydopamine and Its Derivative Materials: Synthesis and Promising Applications in Energy, Environmental, and Biomedical Fields
2014 Standout
Three Decades of β-Lactamase Inhibitors
2010 Standout
Carbapenem Activities against Pseudomonas aeruginosa : Respective Contributions of OprD and Efflux Systems
1999
Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations
2009
Pharmaceuticals and personal care products in the environment: agents of subtle change?
1999 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli
1996
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
2005
2015 ESC Guidelines for the management of infective endocarditis
2015 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
Transferable Mechanisms of Quinolone Resistance from 1998 Onward
2019
Guidelines for Treatment of Candidiasis
2004 Standout
ANTIMICROBIAL-RESISTANT PATHOGENS IN THE 1990s
1996
In Vitro Activities of Garenoxacin (BMS-284756) against 170 Clinical Isolates of Nine Pasteurella Species
2002
Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia
1998 Standout
Bacteroides: the Good, the Bad, and the Nitty-Gritty
2007 Standout
Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat
2001 Standout
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
2012
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Works of B Kolek being referenced
In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin
2000
Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa
1995
Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides
1995
Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2
1995
In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity
1995
Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays
1993
In Vitro and In Vivo Activities of a Novel Cephalosporin, BMS-247243, against Methicillin-Resistant and -Susceptible Staphylococci
2002
In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184
1995
Antibacterial Spectrum of a Novel Des-Fluoro(6) Quinolone, BMS-284756
2000
Antibacterial activity of BMS-180680, a new catechol-containing monobactam
1997
Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents
2001
Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus
1993